Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
1 report, 1 independent
Updated Sep 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Cedars-Sinai Medical Center
hospital in Los Angeles, California, United States
Nothing else this week.
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Matricelf Ltd. is seeking feedback from the FDA regarding its clinical trial design. The company is currently listed on the Tel Aviv Stock Exchange with plans for a dual listing to support its transition.